Related Experiment Video
Updated: Dec 6, 2025
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides
1Initos Pharmaceuticals LLC, Chapel Hill, NC 27514-7631, USA.
Abstract:
Signal transduction pathways play key roles in the initiation, progression and dissemination of cancer. Thus, signaling molecules are attractive targets for cancer therapeutics and enormous efforts have gone into the development of small molecule inhibitors of these pathways. However, regrettably, there has been only moderate progress to date, primarily in connection with the RAS signaling pathway. Oligonucleotide-based drugs potentially offer several advantages for addressing signaling pathways, including their exquisite selectivity and their ability to exploit both enzymatic and nonenzymatic targets. Nonetheless, there are problems inherent in the oligonucleotide approach, not the least being the challenge of effectively delivering these complex molecules to intracellular sites within tumors. This survey article will provide a selective review of recent studies where oligonucleotides were used to address cancer signaling and will discuss both positive aspects and limitations of those studies. This will be set in the context of an overview of various cancer signaling pathways and small molecule approaches to regulate those pathways. The survey will also evaluate the challenges and opportunities implicit in the oligonucleotide-based approach to cancer signaling and will point out several possibilities for future research.
Insights
Oligonucleotide drugs show promise for targeting cancer signaling pathways due to their selectivity. However, challenges remain in delivering these complex molecules effectively to tumor cells for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Signal transduction pathways are crucial in cancer initiation, progression, and metastasis.
- Small molecule inhibitors targeting these pathways have shown moderate success, particularly for the RAS pathway.
- Oligonucleotide-based drugs offer high selectivity for signaling molecules and can target enzymatic and non-enzymatic sites.
Purpose of the Study:
- To review recent studies on oligonucleotide use in targeting cancer signaling pathways.
- To discuss the advantages and limitations of oligonucleotide-based cancer therapeutics.
- To evaluate challenges and opportunities for future research in this field.
Main Methods:
- Selective review of recent literature on oligonucleotide-based cancer signaling research.
- Overview of cancer signaling pathways and current small molecule inhibitor approaches.
- Analysis of delivery challenges and potential solutions for oligonucleotide therapeutics.
Main Results:
- Oligonucleotides demonstrate potential for precise targeting of cancer signaling pathways.
- Significant challenges exist in achieving effective intracellular delivery of oligonucleotides to tumors.
- Current research highlights both the promise and the hurdles in developing oligonucleotide-based cancer drugs.
Conclusions:
- Oligonucleotide therapeutics represent a promising but challenging frontier in cancer signaling research.
- Overcoming delivery barriers is critical for realizing the full potential of these agents.
- Future research should focus on innovative delivery strategies and further exploration of oligonucleotide applications in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:18Cancer
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...